The late stage of Parkinson's -results of a large multinational study on motor and non-motor complications

Parkinsonism Relat Disord. 2020 Jun:75:91-96. doi: 10.1016/j.parkreldis.2020.05.016. Epub 2020 May 21.

Abstract

Introduction: There is little information on the late stages of parkinsonism.

Methods: We conducted a multicentre study in 692 patients with late stage parkinsonism in six European countries. Inclusion criteria were disease duration of ≥7 years and either Hoehn and Yahr stage ≥4 or Schwab and England score of 50 or less.

Results: Average disease duration was 15.4 (SD 7.7) years and mean total UPDRS score was 82.7 (SD 22.4). Dementia according to MDS-criteria was present in 37% of patients. Mean levodopa equivalence dose was 874.1 (SD 591.1) mg/d. Eighty two percent of patients reported falls, related to freezing (16%) or unrelated to freezing (21% of patients) or occurring both related and unrelated to freezing (45%), and were frequent in 26%. Moderate-severe difficulties were reported for turning in bed by 51%, speech by 43%, swallowing by 16% and tremor by 11%. Off-periods occurred in 68% and were present at least 50% of the day in 13%, with morning dystonia occurring in 35%. Dyskinesias were reported by 45% but were moderate or severe only in 7%. Moderate-severe fatigue, constipation, urinary symptoms and nocturia, concentration and memory problems were encountered by more than half of participants. Hallucinations (44%) or delusions (25%) were present in 63% and were moderate-severe in 15%. The association with overall disability was strongest for severity of falls/postural instability, bradykinesia, cognitive score and speech impairment.

Conclusion: These data suggest that current treatment of late stage parkinsonism in the community remains insufficiently effective to alleviate disabling symptoms in many patients.

Keywords: Disability; Late-stage parkinsonism; Motor features; Non-motor symptoms; Prevalence.

Publication types

  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aged, 80 and over
  • Disease Progression*
  • Europe / epidemiology
  • Female
  • Humans
  • Longitudinal Studies
  • Male
  • Parkinson Disease / complications*
  • Parkinson Disease / epidemiology
  • Parkinson Disease / physiopathology*
  • Prevalence
  • Severity of Illness Index*